Hypofractionated SBRT For Prostate Cancer

Adam Olson163 enrolled

Overview

The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at 2 years following hypofractionated stereotactic body radiation therapy for low and intermediate risk prostate cancer.

Radiosurgery should be ideal for treating prostate cancer because: * targeting accuracy for static targets is excellent, with an error of about 1mm, * it can adjust for intra-fractional organ motion, reducing the volume of the target PTV and therefore the dose to surrounding organs, * by using over one-hundred non-conplanar beams, the dose gradient between the prostate and surrounding tissues may be superior to that achieved with conventional linear accelerators, * the radiobiology of prostate cancer may favor large dose per fractions.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

163

Conditions

Prostate Cancer

Interventions

Stereotactic Body Radiation TherapyRADIATION

36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven prostate adenocarcinoma * Gleason score 2-7 * Biopsy within one year of date of registration * Clinical stage T1b-T2b, N0-Nx, M0-Mx (AJCC 6th Edition) * T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, CT, and/or MRI) * M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous metastases. * PSA ≤ 20 ng/dL * Patients belonging in one of the following risk groups: * Low: CS T1b-T2a and Gleason 2-6 and PSA ≤ 10, or * Intermediate: CS T2b and Gleason 2-6 and PSA ≤ 10, or CS T1b-T2b, and Gleason 2-6 and PSA ≤ 20 ng/dL, or Gleason 7 and PSA ≤ 10 ng/dL * Prostate volume: ≤ 100 cc * Determined using: volume = π/6 x length x height x width * Measurement from CT or ultrasound ≤90 days prior to registration. * ECOG performance status 0-1 * Completion of patient questionnaires:FACT-G questionnaire, AUA questionnaire, EPIC-26 questionnaire, SHIM questionnaire, Utilization of Sexual Medications/Devices questionnaire * Consent signed. Exclusion Criteria: * Prior prostatectomy or cryotherapy of the prostate * Prior radiotherapy to the prostate or lower pelvis * Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion. * Chemotherapy for a malignancy in the last 5 years. * History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years. * Hormone ablation for two months prior to enrollment, or during treat

Locations (1)

UPMC Hillman Cancer Center - Shadyside Radiation Oncology

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Rate of Acute Grade 3 or Higher GI and GU Toxicities

Number of patients experiencing acute grade 3 or higher GI and GU toxicities. Acute toxicities are those occurring within 90 days of start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

Time frame: Up to 90 days

Rate of Late Grade 3 or Higher GI and GU Toxicities

Number of patients experiencing late grade 3 or higher GI and GU toxicities. Late toxicities are those occurring after 90 days post start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

Time frame: After 90 days post-treatment, up to 5 years per patient

Biochemical Disease-Free Survival Rate (bDFS)

Biochemical Disease-Free Survival (bDFS) as defined by Phoenix and ASTRO. Biochemical progression-free survival events were defined as PSA of ≥ 0.4 ng/mL following postoperative radiotherapy, PSA \> 2.0 ng/mL at any time, clinical progression, initiation of non-protocol hormone therapy, and death from any cause.

Time frame: Up to 5 years

Secondary Outcomes

Rate of Local Failure

Proportion of patients with 'local failure', which is defined as clinical evidence local recurrence. Clinical failure includes a palpable abnormality that has increased in size, failure of regression of a palpable abnormality, or redevelopment of a prostate abnormality after complete response, further confirmed by prostate biopsy.

Time frame: Up to 5 years

Rate of Distant Failure

Proportion of patients with 'distant failure' (includes regional failure) which is defined as documented clinically via bone scan, CT or other imaging study that shows metastatic disease (disease located distant from the prostate area).

Time frame: Up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.